← Companies|Maze Ther
Ma

Maze Ther

San Francisco CAFounded 201950 employees
Private CapbiotechPrivateRare DiseaseNeurology
Platform: Rare Lysosomal
Market Cap
N/A
All Drugs
2
Clinical Trials
3
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (2 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
DoxalucimabMAZ-7746Phase 1/21DegraderBETPRMT5iOCD
BemarelsinMAZ-9243Phase 2/32RadioligandCGRPAuroraAiHNSCCLGS
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (3)
2027-12-24
Doxalucimab Ph2 Data
OCD
Ph2 Data
2029-02-28
Bemarelsin Ph3 Readout
HNSCC
Ph3 Readout
2030-02-14
Bemarelsin Ph3 Readout
HNSCC
Ph3 Readout